General
Moderna to ask US and European regulators to allow emergency use of COVID-19 vaccine
Pharmaceutical company Moderna Inc. has said it will ask US and European regulators to allow emergency use of its COVID-19 vaccine, so that it can be widely distributed.
Key points:
- Results from a late-stage study show the vaccine was 94.1 per cent effective with no serious safety concerns
- Moderna said the shot was consistently effective across age, race, ethnicity and gender demographics
- US Food and Drug Administration advisers are scheduled to meet on December 17 to review the trial data
The company said full late-stage study results had confirmed the shots offered strong protection, and that its vaccine was 94.1 per cent effective, with no serious safety concerns.
It also reported a 100 per cent success rate in preventing severe cases.
-
General13 hours agoIvan Cleary says Panthers trainer Corey Bocking ‘struggling’ after receiving five-match suspension
-
General24 hours agoFlash floods in India wash away village, kill four and leave over 50 missing
-
Noosa News22 hours agoSXSW Sydney Is Hosting a 14-Hour All-Day ‘Freaks and Geeks’ Marathon as Part of Its 2025 Paul Feig Retrospective
-
General22 hours agoIsrael’s war in Gaza faces difficult path forward after release of hostage videos